Sjögren Syndrome with Positive Serum Cryoglobulins and Symptomatic Cryoglobulinemia

This protocol addresses Sjögren syndrome in patients who have positive serum cryoglobulins with symptomatic cryoglobulinemia and evidence of active systemic disease — a distinct subset requiring targeted management.

Clinical Scenario

Sjögren syndrome presenting alongside symptomatic cryoglobulinemia and positive serum cryoglobulins in the context of active systemic disease. The best indication for intervention is for symptoms linked to cryoglobulinemia-associated vasculitis. Treatment of systemic disease is tailored to organ-specific severity using established disease activity definitions.

Treatment Approach (Partial Overview)

The approach to active systemic disease in this setting involves glucocorticoid therapy, with the specific route and intensity guided by disease severity. Glucocorticoids are used at the minimum dose and duration necessary to control active disease.

The complete regimen — including severity-stratified dosing guidance and sequencing — is available in the full protocol below.

Treatment Goals

The primary therapeutic target is a reduction of ≥3 points in the global ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) score, reflecting meaningful control of systemic disease activity.

Instant Access to Structured Evidence-Based Regimens

References

The best indication is probably for symptoms linked to cryoglobulinemic-associated vasculitis.
Treatment of systemic disease should be tailored to organ-specific severity using the ESSDAI definitions.
GCs should be used at the minimum dose and length of time necessary to control active systemic disease.
GC (recommended dose in mg/kg/day); short-term course whenever possible; consider methylprednisolone pulses in severe cases.
With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of ≥3 points in the global ESSDAI score.

DOI: 10.1136/annrheumdis-2019-216114

View source ↗